This past week three IPOs debuted, five updated terms and three new deals filed.<\/p>\n
It was a tough week for many deals planning to come to market as just three of the eleven IPOs on the schedule priced and debuted. The deal in highest demand this week, Columbia Pipeline Partners (NYSE:CPPL)<\/strong> <\/a>upsized its offering and priced $2.00 above range (23.00). The deal opened at $28.00 for a 22% boost above the offering price. Easterly Government Properties (NYSE: DEA)<\/strong><\/a> fared well as \u2018DEA\u2019 opened $1.25 above the $15.00 mid-range pricing. The only other deal to come to market, Nexvet Biopharma (Nasdaq: NVET)<\/strong><\/a>, needed to be priced $3.00 below the range ($10.00) and, even then, the deal opened 9% below the offering price.<\/p>\n It should be noted that of the eight deals intended to debut this past week, but didn\u2019t, five of them have hopes of coming this week. Infraredx (Nasdaq: REDX)<\/a>, Inotek Pharmaceuticals (Nasdaq: ITEK)<\/a>, AltheaDx (Nasdaq: IDGX)<\/a><\/strong> and Eyegate Pharmaceuticals (Nasdaq: EYEG)<\/strong> <\/a>are to be considered \u2018Day-to-Day\u2019. Additionally, Check-Cap (Nasdaq: CHEK)<\/strong> <\/a>is now scheduled for a February 19th debut. Please refer to last week\u2019s IPO report as well as last week\u2019s advisories for more information about the previously mentioned deals.<\/p>\n Also of note, three deals that were scheduled to debut this week were officially postponed by their respective underwriters: Advanced Accelerator Applications (Nasdaq: AAAP)<\/a>, Carbylan Therapeutics (Nasdaq: CBYL) <\/a><\/strong>and Asante Solutions (Nasdaq: PUMP)<\/strong>.<\/a><\/p>\n There are seven IPOs on the schedule for this week and, at this point, we are hearing early, positive street chatter on….(Subscription Needed)<\/a><\/p>\n Here is the IPO schedule<\/a> for next week.<\/p>\n